Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.400
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Innate Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Innate Pharma stock have an average target of 5.75, with a low estimate of 2.00 and a high estimate of 8.00. The average target predicts an increase of 310.71% from the current stock price of 1.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Innate Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +257.14% | Apr 7, 2026 |
| BTIG | BTIG | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +471.43% | Mar 12, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +257.14% | Oct 29, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +471.43% | Oct 29, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $2 | Buy → Hold | Downgrades | $10 → $2 | +42.86% | Sep 18, 2025 |
Financial Forecast
Revenue This Year
25.25M
from 9.01M
Increased by 180.36%
Revenue Next Year
15.70M
from 25.25M
Decreased by -37.81%
EPS This Year
-0.48
from -0.55
EPS Next Year
-0.97
from -0.48
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 57.1M | 18.7M | |||||
| Avg | 25.2M | 15.7M | |||||
| Low | 5.9M | 13.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 534.3% | -26.0% | |||||
| Avg | 180.4% | -37.8% | |||||
| Low | -34.8% | -48.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.43 | -1.01 | |
| Avg | -0.48 | -0.97 | |
| Low | -0.59 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.